RxDoctor Payments Data

Gabriela Alatorre, APRN

Nurse Practitioner · Phoenix, AZNPI 1336605997

Payments from drug & device makers

$5,755in general payments, 2019–2025

Across 133 payments — averaging $43.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Bristol Myers Squibb$1K
  • Pfizer$623
  • Amgen$404
  • Incyte Corporation$271
  • plus $838 from 7 others

What the payments were for

  • Food & beverage$5,13889%
  • Education$61611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,755 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$124,960
Medicare patients
495
Services billed
1,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide38$808,918
RevlimidLenalidomide43$786,087
VenclextaVenetoclax28$366,166
EliquisApixaban39$32,111
XareltoRivaroxaban31$24,242
Acyclovir286$5,607
Colestipol Hcl28$3,317
Dexamethasone127$1,760
Pregabalin37$564
Gabapentin33$309
Oxycodone Hcl15$286
Omeprazole18$227
Pantoprazole Sodium16$226
Lorazepam26$209
Prochlorperazine Maleate17$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$1,115$808,91838 claims
Bristol Myers SquibbRevlimid$1,046$786,08743 claims
PfizerEliquis$623$32,11139 claims
Johnson & JohnsonXarelto$1,459$24,24231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →